Effect of branched-chain amino acids supplementation for patients with non alcoholic fatty liver disease

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: Branched‐chain amino acids CONDITION: nonalcoholic fatty liver disease PRIMARY OUTCOME: To evaluate the liver function and insulin resistance at 12 weeks INCLUSION CRITERIA: 1. Patient with fatty liver. 2. Patient with insulin resistance (HOMA‐R>=2) or hyperglycemia [fasting blood glucose >=126mg/dl or (blood glucose at 2 hr)>=200mg/dl in oral glucose tolerance test]. 3. Patient with abnormal ALT and/or ganma‐GTP.
Epistemonikos ID: 15da2d9fdbbd1ff022e5e12be0db21bce2f918a1
First added on: Aug 22, 2024